Spectral Medical Featured in New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Septic Shock
08 September 2023 - 2:13PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT), a late-stage theranostic company advancing
therapeutic options for sepsis and septic shock, is pleased to
announce a new episode of The Balancing Act focused on advancing
therapeutic options for sepsis and endotoxic septic shock (ESS).
This compelling episode will provide insight into endotoxic septic
shock, its causes, symptoms and treatment options. Additionally,
the episode will capture interviews with physicians and clinical
trial clinicians involved in Spectral’s pivotal TIGRIS trial which
is poised to vastly improve outcomes with a targeted diagnostic
test (EAA) and its lead product PMX (Toraymyxin™ PMX-20R) for
treatment of patients with endotoxic septic shock.
If you are not able to catch the live episode, you can also find
it on YouTube:
https://www.youtube.com/user/TheBalancingAct
Dr. John Kellum, Chief Medical Officer of
Spectral Medical, commented, “We continue to work aggressively to
complete the enrollment of our Tigris Trial and currently have 72
patients enrolled to date. With an additional three study sites
onboarding in the coming weeks, we could potentially see a further
acceleration of enrollment activity. We are pleased to partner with
The Balancing Act to increase the awareness of sepsis as well as
our ongoing efforts to bring a personalized therapy to help
patients suffering from endotoxic septic shock and hope to bring a
new standard of care to the market.”
About
Spectral
Spectral is a Phase 3 company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic
hemoperfusion device that removes endotoxin, which can cause
sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX is approved for therapeutic use in Japan and
Europe, and has been used safely and effectively on more than
340,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. In July 2022, the U.S. FDA granted
Breakthrough Device Designation for PMX for the treatment of
endotoxic septic shock. Approximately 330,000 patients are
diagnosed with septic shock in North America each year.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information please visit
www.spectraldx.com.
About The Balancing
Act
The Balancing Act® is a morning show created and
produced by BrandStar that offers sensible solutions and
essential information in a fun, entertaining format; providing
resources to help people do life better. The Balancing Act features
everything from delicious recipes, style makeovers and dream
getaways to parenting tips and the latest news in health and
wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT)
on Lifetime®, and find all previously aired episodes
on TheBalancingAct.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the company’s ability to raise capital and
the availability of funds and resources to pursue R&D projects,
the recruitment of additional clinical trial sites, the rate of
patient enrollment, the successful and timely completion of
clinical studies, the success of Baxter’s commercialization
efforts, the ability of Spectral to take advantage of business
opportunities in the biomedical industry, the granting of necessary
approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from
what is currently expected.
The TSX has not reviewed and does not accept responsibility for
the adequacy or accuracy of this statement.
For further information, please contact:
Ali Mahdavi |
David Waldman/Natalya Rudman |
Blair McInnis |
Capital Markets & Investor
Relations |
US Investor Relations |
CFO |
Spinnaker Capital Markets
Inc. |
Crescendo Communications,
LLC |
Spectral Medical Inc. |
416-962-3300 |
212-671-1020 |
416-626-3233 |
am@spinnakercmi.com |
edt@crescendo-ir.com |
bmcinnis@spectraldx.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024